Verily, "eliminated its entire medical devices program" this week. See an open-access story at TechCrunch and a subscription article at Business Insider, Alphabet's life sciences arm,
Alphabet has a market cap of about $2 trillion, of which Google Search is about 80% of revenue. Its life sciences businesses (Verily, Calico) are tiny by comparison.
What Verily Did/Does?
According to a web search by Chat GPT 5, experimental or discontinued projects at Verily included a spoon for tremors (acquied Liftware), a glucose-sensing contact lens, a retinal camera, and miniatured glucose monitors in collaboration with Dexcom.
In a future that is absent "devices," Verily life sciences interests could include AI oriented toward digital health startups, pharma, healthcare systems improvements. Lightpath, for example, is an AI-powered chronic care app in development.
##
In mid-2024, Verily announced it was shifting its headquarters to Dallas-Ft. Worth. Nicole Ward at DallasInnovates.com writes,
- Verily, born as a moonshot project at Google X, has consistently pursued ambitious goals in healthcare technology.
- The company develops advanced tools and solutions to help patients, providers, and researchers navigate the healthcare landscape. Its offerings range from consumer-facing products like diabetes management apps and retinal screening devices to sophisticated data analytics platforms for healthcare professionals.
- Since establishing its Dallas office, Verily has rapidly emerged as a force in Dallas-Fort Worth’s growing healthcare and tech ecosystem.
##
Past leadership at Verily included Dr Amy Abernethy and Dr Andrew Conrad (now at S32 VC). Stephen Gillett is CEO since 2023; prior positions included Symantec (as COO) and Best Buy.
